Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship Available from: http://www.sciencedirect.com/science/article/pii Available from: http://invs.santepubliquefrance.fr/content/download Docetaxel Versus Docetaxel Plus Cisplatin As Front-Line Treatment of Patients With Advanced Non?Small- Cell Lung Cancer: A Randomized, Multicenter Phase III Trial, Mayo Clinic Proceedings [Internet]. Survie des personnes. J Clin Oncol, vol.43013222, issue.113, pp.584-5942602, 2004. ,
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study., Journal of Clinical Oncology, vol.16, issue.7, pp.2459-2465, 1998. ,
DOI : 10.1200/JCO.1998.16.7.2459
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non???Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy, Journal of Clinical Oncology, vol.18, issue.10, pp.2095-2103, 2000. ,
DOI : 10.1200/JCO.2000.18.10.2095
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non???Small-Cell Lung Cancer to Gefitinib, New England Journal of Medicine, vol.350, issue.21, pp.2129-2139, 2004. ,
DOI : 10.1056/NEJMoa040938
Gefitinib or Carboplatin???Paclitaxel in Pulmonary Adenocarcinoma, New England Journal of Medicine, vol.361, issue.10, pp.947-957, 2009. ,
DOI : 10.1056/NEJMoa0810699
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, The Lancet Oncology, vol.13, issue.3, pp.239-246, 2012. ,
DOI : 10.1016/S1470-2045(11)70393-X
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.373, issue.2, pp.123-158, 2009. ,
DOI : 10.1056/NEJMoa1504627
Nivolumab versus Docetaxel in Advanced Nonsquamous Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.373, issue.17, pp.1627-1666, 2015. ,
DOI : 10.1056/NEJMoa1507643
The blockade of immune checkpoints in cancer immunotherapy, Nature Reviews Cancer, vol.12, issue.4, pp.252-64, 2012. ,
DOI : 10.1038/nrc3237
Tumor Immunotherapy Directed at PD-1, New England Journal of Medicine, vol.366, issue.26, pp.2517-2519, 2012. ,
DOI : 10.1056/NEJMe1205943
Mutation, New England Journal of Medicine, vol.372, issue.4, pp.320-350, 2015. ,
DOI : 10.1056/NEJMoa1412082
URL : https://hal.archives-ouvertes.fr/hal-00699117
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.373, issue.19, pp.1803-1816, 2015. ,
DOI : 10.1056/NEJMoa1510665
Pembrolizumab versus Chemotherapy for PD-L1???Positive Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.375, issue.19, pp.1823-1856, 2016. ,
DOI : 10.1056/NEJMoa1606774
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, The Lancet, vol.389, issue.10066, pp.255-65, 2017. ,
DOI : 10.1016/S0140-6736(16)32517-X
Durvalumab after Chemoradiotherapy in Stage III Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.377, issue.20, 2017. ,
DOI : 10.1056/NEJMoa1709937
Immune-related adverse events with immune checkpoint blockade: a comprehensive review, European Journal of Cancer, vol.54, 2016. ,
DOI : 10.1016/j.ejca.2015.11.016
Pulmonary sarcoid-like granulomatosis induced by nivolumab, British Journal of Dermatology, vol.22, issue.4, pp.1060-1063 ,
DOI : 10.1158/1078-0432.CCR-15-1136
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis, Journal of Clinical Oncology, vol.33, issue.7, 2015. ,
DOI : 10.1200/JCO.2014.57.4756
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-smallcell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial, Lancet Oncol, 2017. ,
The RECIST criteria: implications for diagnostic radiologists, The British Journal of Radiology, vol.74, issue.887, pp.983-986, 2001. ,
DOI : 10.1002/1097-0142(19800901)46:5<1286::AID-CNCR2820460533>3.0.CO;2-F
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors, Journal of Nuclear Medicine, vol.50, issue.Suppl_1, pp.122-150, 2009. ,
DOI : 10.2967/jnumed.108.057307
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, Clinical Cancer Research, vol.15, issue.23, pp.7412-7432, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-1624
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements, Clinical Cancer Research, vol.19, issue.14, pp.3936-3979, 2013. ,
DOI : 10.1158/1078-0432.CCR-13-0895
F-FDG PET/CT Imaging in Patients with Advanced Melanoma, Journal of Nuclear Medicine, vol.58, issue.9, pp.1421-1429, 2017. ,
DOI : 10.2967/jnumed.116.188839
02c-026 Is nivolumab safe and effective in ederly and PS2 patients with non small cell lung cancer (NSCLC)? Results of Checkmate 153, J Thorac Oncol, vol.12, issue.1, pp.1286-1287, 2017. ,
Immune???Related Adverse Events as a Biomarker in Non???Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors, The Oncologist, vol.22, issue.10 ,
DOI : 10.1634/theoncologist.2017-0133
The Oncologist, pp.2017-0133, 2017. ,
Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer, Annals of Oncology, vol.640, 2016. ,
DOI : 10.1093/annonc/mdw640
Real life experience with immunotherapy in Netherlands, J Thorac Oncol, vol.0712, issue.1, p.425, 2017. ,
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non???Small Cell Lung Cancer Treated with Nivolumab, Journal of Thoracic Oncology, vol.12, issue.9, 2017. ,
DOI : 10.1016/j.jtho.2017.04.027
Prior radiotherapy does not predict nivolumab response in non-small-cell lung cancer: a retrospective cohort study, Annals of Oncology, vol.51, issue.5, pp.1402-1402, 2017. ,
DOI : 10.1016/S0959-8049(16)31443-5
Pretreatment neutrophil-tolymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-smallcell lung cancer, Lung Cancer, vol.2017106, pp.1-7 ,